|
Gene: RPL22L1 |
Gene summary for RPL22L1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RPL22L1 | Gene ID | 200916 |
Gene name | ribosomal protein L22 like 1 | |
Gene Alias | RPL22L1 | |
Cytomap | 3q26.2 | |
Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | Q6P5R6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
200916 | RPL22L1 | C21 | Human | Oral cavity | OSCC | 6.08e-46 | 1.88e+00 | 0.2678 |
200916 | RPL22L1 | C30 | Human | Oral cavity | OSCC | 5.44e-48 | 4.12e+00 | 0.3055 |
200916 | RPL22L1 | C38 | Human | Oral cavity | OSCC | 3.34e-25 | 3.28e+00 | 0.172 |
200916 | RPL22L1 | C43 | Human | Oral cavity | OSCC | 1.27e-61 | 1.26e+00 | 0.1704 |
200916 | RPL22L1 | C46 | Human | Oral cavity | OSCC | 6.99e-49 | 1.44e+00 | 0.1673 |
200916 | RPL22L1 | C51 | Human | Oral cavity | OSCC | 4.65e-29 | 2.10e+00 | 0.2674 |
200916 | RPL22L1 | C57 | Human | Oral cavity | OSCC | 2.23e-30 | 1.34e+00 | 0.1679 |
200916 | RPL22L1 | C06 | Human | Oral cavity | OSCC | 3.20e-20 | 3.63e+00 | 0.2699 |
200916 | RPL22L1 | C07 | Human | Oral cavity | OSCC | 3.22e-12 | 2.35e+00 | 0.2491 |
200916 | RPL22L1 | C08 | Human | Oral cavity | OSCC | 3.49e-89 | 2.86e+00 | 0.1919 |
200916 | RPL22L1 | C09 | Human | Oral cavity | OSCC | 1.43e-13 | 8.02e-01 | 0.1431 |
200916 | RPL22L1 | LN22 | Human | Oral cavity | OSCC | 2.42e-04 | 1.07e+00 | 0.1733 |
200916 | RPL22L1 | LN38 | Human | Oral cavity | OSCC | 1.81e-15 | 3.09e+00 | 0.168 |
200916 | RPL22L1 | LN46 | Human | Oral cavity | OSCC | 1.11e-22 | 1.24e+00 | 0.1666 |
200916 | RPL22L1 | LP15 | Human | Oral cavity | LP | 1.41e-08 | 2.16e+00 | 0.2174 |
200916 | RPL22L1 | LP17 | Human | Oral cavity | LP | 1.79e-08 | 1.51e+00 | 0.2349 |
200916 | RPL22L1 | SYSMH1 | Human | Oral cavity | OSCC | 1.74e-45 | 1.51e+00 | 0.1127 |
200916 | RPL22L1 | SYSMH2 | Human | Oral cavity | OSCC | 9.24e-45 | 1.67e+00 | 0.2326 |
200916 | RPL22L1 | SYSMH3 | Human | Oral cavity | OSCC | 1.36e-43 | 2.01e+00 | 0.2442 |
200916 | RPL22L1 | SYSMH4 | Human | Oral cavity | OSCC | 3.25e-46 | 1.16e+00 | 0.1226 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
GO:000218125 | Cervix | N_HPV | cytoplasmic translation | 42/534 | 148/18723 | 2.61e-30 | 1.19e-26 | 42 |
GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
GO:00021811 | Colorectum | SER | cytoplasmic translation | 102/2897 | 148/18723 | 1.38e-48 | 8.49e-45 | 102 |
GO:00021812 | Colorectum | MSS | cytoplasmic translation | 108/3467 | 148/18723 | 1.78e-47 | 1.11e-43 | 108 |
GO:00021813 | Colorectum | MSI-H | cytoplasmic translation | 100/1319 | 148/18723 | 1.50e-79 | 8.31e-76 | 100 |
GO:000218116 | Endometrium | AEH | cytoplasmic translation | 104/2100 | 148/18723 | 1.01e-64 | 6.07e-61 | 104 |
GO:000218117 | Endometrium | EEC | cytoplasmic translation | 104/2168 | 148/18723 | 2.53e-63 | 1.52e-59 | 104 |
GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
GO:000218112 | Liver | Cirrhotic | cytoplasmic translation | 120/4634 | 148/18723 | 2.95e-47 | 1.85e-43 | 120 |
GO:000218122 | Liver | HCC | cytoplasmic translation | 132/7958 | 148/18723 | 9.09e-33 | 5.76e-30 | 132 |
GO:000218120 | Oral cavity | OSCC | cytoplasmic translation | 133/7305 | 148/18723 | 1.94e-38 | 2.46e-35 | 133 |
GO:0002181110 | Oral cavity | LP | cytoplasmic translation | 124/4623 | 148/18723 | 5.09e-52 | 3.19e-48 | 124 |
GO:000218118 | Prostate | BPH | cytoplasmic translation | 115/3107 | 148/18723 | 1.08e-60 | 6.68e-57 | 115 |
GO:000218119 | Prostate | Tumor | cytoplasmic translation | 115/3246 | 148/18723 | 1.36e-58 | 8.43e-55 | 115 |
GO:000218129 | Skin | cSCC | cytoplasmic translation | 127/4864 | 148/18723 | 4.83e-53 | 7.57e-50 | 127 |
GO:0002181113 | Thyroid | PTC | cytoplasmic translation | 121/5968 | 148/18723 | 4.32e-36 | 4.54e-33 | 121 |
GO:000218135 | Thyroid | ATC | cytoplasmic translation | 121/6293 | 148/18723 | 1.41e-33 | 1.49e-30 | 121 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0517145 | Cervix | N_HPV | Coronavirus disease - COVID-19 | 47/349 | 232/8465 | 1.79e-20 | 4.86e-18 | 3.80e-18 | 47 |
hsa0301045 | Cervix | N_HPV | Ribosome | 39/349 | 167/8465 | 2.05e-19 | 2.79e-17 | 2.18e-17 | 39 |
hsa0517155 | Cervix | N_HPV | Coronavirus disease - COVID-19 | 47/349 | 232/8465 | 1.79e-20 | 4.86e-18 | 3.80e-18 | 47 |
hsa0301055 | Cervix | N_HPV | Ribosome | 39/349 | 167/8465 | 2.05e-19 | 2.79e-17 | 2.18e-17 | 39 |
hsa03010 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa030101 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
hsa051711 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa030104 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
hsa051714 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
hsa030105 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
hsa051715 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPL22L1 | SNV | Missense_Mutation | novel | c.361N>C | p.Glu121Gln | p.E121Q | Q6P5R6 | protein_coding | deleterious(0) | benign(0.305) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPL22L1 | SNV | Missense_Mutation | novel | c.317N>G | p.Leu106Arg | p.L106R | Q6P5R6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
RPL22L1 | SNV | Missense_Mutation | c.151N>A | p.Leu51Ile | p.L51I | Q6P5R6 | protein_coding | deleterious(0.02) | probably_damaging(0.984) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RPL22L1 | SNV | Missense_Mutation | c.151N>A | p.Leu51Ile | p.L51I | Q6P5R6 | protein_coding | deleterious(0.02) | probably_damaging(0.984) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
RPL22L1 | SNV | Missense_Mutation | rs761781205 | c.313G>A | p.Glu105Lys | p.E105K | Q6P5R6 | protein_coding | tolerated(0.13) | possibly_damaging(0.537) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPL22L1 | SNV | Missense_Mutation | novel | c.55N>A | p.Asp19Asn | p.D19N | Q6P5R6 | protein_coding | tolerated(0.12) | possibly_damaging(0.651) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
RPL22L1 | SNV | Missense_Mutation | c.319C>T | p.Arg107Cys | p.R107C | Q6P5R6 | protein_coding | tolerated(0.12) | benign(0.081) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RPL22L1 | SNV | Missense_Mutation | rs200190593 | c.115N>T | p.Arg39Trp | p.R39W | Q6P5R6 | protein_coding | tolerated(0.18) | benign(0.022) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPL22L1 | SNV | Missense_Mutation | c.319N>T | p.Arg107Cys | p.R107C | Q6P5R6 | protein_coding | tolerated(0.12) | benign(0.081) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR | |
RPL22L1 | SNV | Missense_Mutation | novel | c.23N>T | p.Lys8Met | p.K8M | Q6P5R6 | protein_coding | deleterious(0) | probably_damaging(0.951) | TCGA-56-7823-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |